176
Participants
Start Date
October 7, 2021
Primary Completion Date
February 28, 2028
Study Completion Date
May 30, 2028
Ipatasertib
Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
Cobimetinib
Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
Trastuzumab Emtansine
Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Atezolizumab
Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Bevacizumab
Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Paclitaxel
Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
Giredestrant
Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
Abemaciclib
Abemaciclib will be administered by mouth twice a day during each 28-day cycle
Inavolisib
Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
Palbociclib
Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
Letrozole
Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
Olaparib
Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
Cyclophosphamide
Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
Inavolisib
Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
Hôpitaux Universitaires de Genève, Geneva
Cabrini Hospital, Malvern
Centre Francois Baclesse, Caen
IRCCS S. Raffaele, Milan
Virginia Oncology Associates, Norfolk
CHU Besançon - Hôpital Jean Minjoz, Besançon
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Levine Cancer Institute, Charlotte
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Institut Claudius Regaud, Toulouse
Koc University Medical Faculty; Department of Gynecology & Obstetrics, Istanbul
Centre Eugène Marquis, Rennes
Ohio State University, Columbus
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie, Essen
Washington University School of Medicine, St Louis
Universitätsklinikum Mannheim, Mannheim
Centre Leon Berard, Lyon
A.O. U. Consorziale Policlinico di Bari, Bari
University of Oklahoma Health Sciences Center, Oklahoma City
Groupe Hospitalier Diaconesses, Paris
Texas Oncology - Gulf Coast, The Woodlands
Istituto Tumori Napoli, Napoli
UCSF Helen Diller Family CCC, San Francisco
Gustave Roussy, Villejuif
University of Washington - Seattle Cancer Care Alliance, Seattle
Princess Margaret Cancer Center, Toronto
McGill University Health Centre - Glen Site, Montreal
Gynekologicko-porodnicka klinika, Prague
Policlinico Universitario Agostino Gemelli, Rome
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Institutio Catalan De Oncologia, Barcelona
Adana Baskent University Medical Faculty; Oncology, Adana
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü, Ankara
Western General Hospital, Edinburgh
University College London Hospitals NHS Foundation Trust - University College Hospital, London
GOG Foundation
NETWORK
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Hoffmann-La Roche
INDUSTRY